Experimental Drug For Multi-Drug Resistant TB Shows Promise In Trial

When added to the mix, a new experimental drug known as TMC207 appeared to make a cocktail of background drugs five times more powerful in successfully treating patients with multidrug resistant tuberculosis (MDR-TB). The study is published in the 4 June issue of the New England Journal of Medicine, NEJM and was the work of Dr David McNeeley and colleagues. McNeeley works for Tibotec, the subsidiary of Johnson & Johnson that is developing the drug.

More: continued here

Filed under: Clinical Trials on June 5th, 2009